Press Release
GM Seed Grew 5.90 Per Cent on 2.00 Per Cent More Land — and One US Herbicide Ruling Took 23 Per Cent Off a Cotton Seed Business While World Cotton Area Fell 3.8
The global market for genetically modified and biotech seed — the commercial value farmers pay for seed carrying engineered traits, together with the trait royalties embedded in that price — was worth USD 26.15 billion in 2025 and is forecast to reach USD 41.37 billion by 2033, a compound annual growth rate of 5.90%. It is 33.4% of the USD 78.40 billion global commercial seed market.
Almost none of the additional money is land. GM planted area reached a record 216.0 million hectares in 2025 across 30 countries — 28.2% of the 765.9 million hectares of crop area this report tracks — and the forecast takes it only to 253.1 million hectares, or 2.00% a year. Revenue per GM hectare carries the rest: USD 121.1 to USD 163.5, 3.82%.
That makes the price of this market its least secure number, and 2025 demonstrated exactly how. A single United States herbicide label vacatur removed dicamba as a usable chemistry, and with it the value of every tolerance trait built around it. Bayer’s cotton seed and traits revenue fell 23% in that year. World GM cotton area fell 3.8%. The legal event was 6.1 times the agronomic one — and it happened inside one fiscal year, to a product the company had already sold.
Market Snapshot
| Base year | 2025 |
| Base-year market value | USD 26.15 billion |
| Forecast market value, 2033 | USD 41.37 billion |
| CAGR, 2026–2033 | 5.90% |
| Historical CAGR, 2021–2025 | 7.20% |
| GM planted area, 2025 | 216.0 million hectares |
| GM planted area, 2033 | 253.1 million hectares |
| GM area CAGR, 2026–2033 | 2.00% |
| Revenue per GM hectare, 2025 | USD 121.1 |
| Revenue per GM hectare, 2033 | USD 163.5 |
| Revenue per hectare CAGR | 3.82% |
| Share of tracked global crop area, 2025 | 28.2% of 765.9 million hectares |
| Share of the commercial seed market | 33.4% of USD 78.40 billion |
| Countries cultivating GM crops, 2025 | 30 |
| Largest single market | United States, 79.7 million hectares — 36.9% of world GM area |
| Fastest-growing significant market | China, +79.0% in area, 2025 |
| Largest crop by value | Maize, USD 12.35 billion, 47.2% |
| Largest trait segment | Stacked herbicide tolerance and insect resistance, 62.0% of value |
| Value at stake on expiring or contested exclusivity | Herbicide tolerance alone, 27.0% of value |
The growth rate is a price assumption, and the price is a legal one
The historical period and the forecast differ in a way the headline conceals. Between 2021 and 2025 this market compounded at 7.20%: area at 2.46%, revenue per hectare at 4.63%. From 2026 to 2033 it compounds at 5.90%: area at 2.00%, revenue per hectare at 3.82%.
The step-down is 1.30 percentage points, and 0.80 of it — 62% — is the price rate, not the area rate. That distinction is not academic. The report explains the step-down with two non-recurring events: the 2022 commodity price spike that reset seed price expectations upward across the Americas, and the 2024–2025 acceleration in Chinese approvals. The arithmetic puts most of the deceleration in a line the dicamba episode proved is contingent on a label rather than on a market.
Stated as a counterfactual: hold revenue per GM hectare at its historical 4.63% and 2033 is USD 44.00 billion rather than 41.37. USD 2.63 billion — 17.3% of the entire increment — is simply the price rate decelerating from 4.63 to 3.82.
| Component | 2021–2025 | 2026–2033 | Change |
|---|---|---|---|
| Market value | 7.20% | 5.90% | −1.30 pts |
| Planted area | 2.46% | 2.00% | −0.46 pts |
| Revenue per hectare | 4.63% | 3.82% | −0.81 pts |
On the USD 15.22 billion increment, an endpoint bridge across the report’s own area and revenue-per-hectare series gives USD 4.49 billion from area (29.5%), USD 9.16 billion from revenue per hectare (60.2%) and USD 1.57 billion of interaction (10.3%). The report describes this as “roughly one third” from area, which the bridge supports to within four points. It does not state which method produced the figure — the sixth report in this seed cluster to publish a decomposition without naming its method, and the one where the gap between methods is smallest.
China is the only large area still converting, and it is converting on a schedule
The 2024 demonstration programme covered eight provinces and roughly 1.07 million mu. In 2025 it extended to thirteen provinces and passed 30 million mu. The 2026 season is the first conducted under ordinary commercial planting rules: maize is targeted at 57.85 million mu — 3.86 million hectares — and soybean at 1.03 million mu, across 23 provinces plus the Xinjiang Corps and Beidahuang.
That is 8.9% of a national maize seed area of about 650 million mu. Cumulative variety approvals reached 239 by the fourth batch in late 2026 — 219 maize and 20 soybean — and Beijing Dabeinong’s events sit inside 133 of the 219 maize varieties, 60.73%, including 38 of the 59 approved in the most recent batch. Its DBN9936 and DBN3601T traits are the commercial anchors; Yuan Longping High-Tech and its associated platform hold five transformation event biosafety certificates of their own.
The reason the policy has held is field performance rather than policy ambition: efficacy above 90% against fall armyworm and stem borer, average yield gains of 8.5%, and a measured cost-and-revenue benefit of RMB 132.5 per mu in maize. China also completed the regulatory chain that makes routine planting possible — biosafety certificate, variety approval and, for herbicide-tolerant events, chemistry registration — and did not complete it until 2024. That sequence, not the approval count, is what separates a demonstration from a market.
Where the remaining headroom actually is — and how small one season of it is
Global maize is 210.4 million hectares and GM maize is 35.8% of it, which leaves 135.1 million hectares unconverted, overwhelmingly in Asia and Africa. Cotton is 76.7% GM and soybean 73.9%: the two crops that built this industry have almost nothing left to convert.
Set China’s entire 2026 target against that maize figure and it is 2.9%. The largest state-directed regulatory opening in the world, executed by the state with the most capacity to execute it, moves less than three per cent of the identified headroom in its first full commercial season. That is the honest measure of how long this forecast’s area line takes to matter.
| Crop | GM share of world area, 2025 |
|---|---|
| Cotton | 76.7% |
| Soybean | 73.9% |
| Maize | 35.8% |
| Canola | 24.8% |
| Sugar beet | 9.7% |
| Alfalfa | 3.1% |
| All GM crops | 28.2% |
The trait business is becoming a licensing business
In early 2026 Corteva settled all litigation with Bayer for USD 610 million in cash, funded largely from 2025 free cash flow. The settlement pulled Corteva’s royalty-neutrality target forward two years to 2026, converted it from a net royalty payer to a net out-licensor, and set a target of USD 1 billion of net royalty income by 2035. It also brought forward the availability of triple-stack maize traits for out-licensing by roughly five years, to as early as 2027, advanced third-generation above-ground insect traits by about two years, and opened the US cotton out-licensing market. The company expects the agreement to contribute around USD 1 billion of aggregate earnings upside over the next decade.
Two of the four largest event owners have therefore agreed to compete on placement and germplasm rather than on access denial. Licensed and out-licensed routes to market were 32.7% of 2025 value and are forecast at 35.0% by 2033 — 6.81% a year against the market’s 5.90. That is the cleanest single indicator in the report of where the economics are moving.
The consequence for the bag is specific. Access to elite traits is becoming purchasable rather than merely licensable, which widens the number of seed brands selling GM seed into the same geography and compresses retail margin, even as it expands the event owner’s royalty base. A stacked maize bag in North America already carries a trait component of 30% to 40% of the bag price, sometimes paid to two or three event owners at once. The parties most exposed are mid-sized seed businesses with neither proprietary germplasm nor proprietary events: they now face the same trait cost as larger rivals with less scale to absorb it.
Gene editing has split the regulatory world, and the split has a date
Regulation (EU) 2026/1388 was adopted on 17 June 2026, entered into force on 16 July 2026 and applies from 17 July 2028. It creates two categories: category 1 NGT plants meeting defined equivalence criteria are treated broadly like conventionally bred plants, verified rather than fully risk-assessed, while category 2 plants remain inside the GMO regime with adaptations. Until July 2028 the existing GMO rules apply to every NGT, and no crop developed exclusively through NGTs is authorised for food or feed in the European Union today. The delegated and implementing acts that make category 1 verification operational are due by the same date, as is EFSA’s guidance.
Europe is 0.6% of this market. That is why the regulation reads as an option on the 2033 number rather than a contributor to it — and why the assumption most likely to be wrong in this forecast is the European timeline rather than the technology.
Gene-edited and NGT-derived seed is 1.3% of 2025 value, USD 340 million, and it grows at 16.6% a year — faster than any other segment in the report, by a wide margin. It reaches 2.8% by 2033, or about USD 1.16 billion. That is the honest size of the near-term prize: the fastest-growing segment in a USD 41 billion market will still be a billion-dollar segment at the end of the forecast, and it is contingent on a verification procedure that does not yet exist in draft.
Segmentation: maize, stacks, and the smallest segment that grows fastest
By crop, maize leads at USD 12.35 billion, 47.2% of 2025 value, ahead of soybean at 31.7%, cotton at 13.0%, canola at 5.9% and all other GM crops at 2.1%. Maize and soybean together are 78.9% of value and will be 80.9% in 2033 — the market is becoming more concentrated in its two established crops, not less.
By trait, stacked herbicide tolerance plus insect resistance is 62.0% of value rising to 67.2%, a 6.97% rate. Herbicide tolerance alone is 27.0% and is the segment most exposed to generic erosion, because a tolerance trait is worth exactly what the label permitting its chemistry is worth — the dicamba dependency, expressed as a share of the market. Insect resistance alone is 11.0% and is concentrated in cotton.
By route to market, branded seed is 67.3% and licensed or out-licensed technology 32.7%, rising to 35.0%. By technology generation, established transgenics are 98.7% of 2025 value and gene-edited seed 1.3%. The report’s four segment families are internally consistent: the crop shares sum to 26.13 against the 26.15 control, a 0.1% difference attributable to rounding.
Regional analysis
North America is USD 14.00 billion, 53.5% of the market and its slowest region at 4.83%. Adoption is saturated, and the dicamba vacatur cut directly into soybean and cotton trait revenue in the largest single country. South America is USD 8.50 billion, 32.5%, at 6.34%, with Brazil now planting only 5 million hectares less GM crop than the United States — the narrowest gap on record — and Argentina carrying 91 approved events across nine crops after 13 new approvals across 2024–2025. Asia-Pacific is the fastest-growing significant region, USD 2.30 billion to USD 4.60 billion at 9.05%. Europe is USD 0.15 billion at 0.6%. The Middle East and Africa are USD 1.20 billion at 4.60%, and Ghana became the thirtieth cultivating country in 2025 with GM cowpea.
| Region | 2025 (USD bn) | Share | CAGR | 2033 at published rate (USD bn) |
|---|---|---|---|---|
| North America | 14.00 | 53.5% | 4.83% | 20.42 |
| South America | 8.50 | 32.5% | 6.34% | 13.90 |
| Asia-Pacific | 2.30 | 8.8% | 9.05% | 4.60 |
| Europe | 0.15 | 0.6% | not published | not published |
| Middle East and Africa | 1.20 | 4.6% | 4.60% | 1.72 |
| Total | 26.15 | 100.0% | 5.90% | 41.37 |
The five regions sum exactly to USD 26.15 billion in 2025. They do not compound to USD 41.37 billion in 2033. At their published rates, and holding Europe flat at USD 0.15 billion, they reach USD 40.79 billion — leaving USD 0.58 billion unaccounted, which would require Europe to grow at 21.9% a year to close. Disclosed here rather than absorbed silently: the gap is 1.4% of the 2033 control, and it sits entirely in the region the report separately treats as a 2028 option.
Competitive landscape
Event ownership in this industry is one of the most concentrated technology markets in the world; seed selling is not. Four companies hold the overwhelming majority of commercial events for maize, soybean, cotton and canola, and the capital required to generate and register a new event keeps new entrants at the discovery layer rare. Below that layer thousands of independent seed companies, regional multipliers and cooperatives sell GM seed under licence, and their aggregate share of the bag is larger than any single brand.
| Company | FY2025 seed measure | Change | Note |
|---|---|---|---|
| Bayer Crop Science | EUR 11,136m Seeds and Traits | +5% currency- and portfolio-adjusted | Corn EUR 7,149m, +13%; soybean EUR 2,214m, −8%; cotton EUR 442m, −23% on dicamba vacatur |
| Corteva Agriscience | USD 9,898m seed net sales | +4% | Corn USD 7,002m; seed EBITDA USD 2,636m, +19%, margin +340bp |
| Syngenta Group | Seeds sales | +0.7% | Volume −0.5%, price +1.3%; North America restructuring |
| Beijing Dabeinong | Trait share of approved maize varieties | 133 of 219 | 60.73% of China’s approved maize list |
Bayer Crop Science reported Crop Science sales of EUR 21,622 million, up 1.1% adjusted, with Seeds and Traits at EUR 11,136 million. Corn seed and traits were the engine at EUR 7,149 million, up 13% adjusted on higher planted area across all regions and additional licensing revenue. Soybean fell 8% to EUR 2,214 million and cotton fell 23% to EUR 442 million, both attributed to the dicamba vacatur and lower planted area. Vegetable seeds grew 8% to EUR 788 million. Segment EBITDA before special items was EUR 4.2 billion at a 19.4% margin, flat year on year — a result that reads as stability and is in fact corn growth absorbing a regulatory shock.
Corteva reported Seed net sales of USD 9,898 million, up 4%, on 3% price/mix and 2% volume, with seed operating EBITDA of USD 2,636 million, up 19%, and a margin improvement of roughly 340 basis points. Corn was USD 7,002 million, soybean USD 1,878 million and other oilseeds USD 644 million. By region North America was USD 6,271 million, Latin America USD 1,614 million, EMEA USD 1,560 million and Asia-Pacific USD 453 million, summing exactly to the segment total. Argentina reached more than 30% penetration of Enlist E3 soybean technology, primarily through out-licensing, and Brazil is expected to reach double-digit Conkesta trait penetration.
Syngenta grew Seeds sales 0.7%, with volume down 0.5% and price up only 1.3%, while executing a North American restructuring rather than pursuing share. Group net income was USD 993 million against USD 269 million in 2024, with free cash flow of USD 1.2 billion. BASF remains a meaningful but smaller participant, concentrated in canola and cotton with less trait exposure than the three above it. And the genuinely new entrant is Chinese: Dabeinong’s 60.73% share of a national approval list makes it structurally important while generating a fraction of Bayer’s or Corteva’s revenue — which is the correct way to read a company whose asset is approval rather than volume.
The portfolio event of the cycle is Corteva’s announced intention, disclosed on 1 October 2025, to separate Seed and Crop Protection into two standalone publicly traded companies in a transaction intended to be tax-free. A standalone seed business with USD 9,898 million of net sales, a 19% operating EBITDA improvement and gene editing, hybrid wheat and out-licensing as stated growth vectors is a different investment proposition from a combined input supplier — and the separation is the clearest public statement that the two halves of the input industry have stopped sharing economics.
Scope, method and boundary disclosures
Scope. 2025 base year, 2033 horizon, USD, global. The market covers the price farmers pay for seed carrying engineered traits, including the trait royalties embedded in the bag. It excludes conventional seed, separately invoiced agronomic services and the crop protection chemistry the traits tolerate — the last of which the 2025 dicamba episode showed is not a clean exclusion so much as a dependency.
Method. Market size is triangulated from three independent directions: a GM share applied to the USD 78.40 billion global commercial seed base, a bottom-up aggregation of disclosed tier-1 seed and trait revenue adjusted to the GM-bearing portfolio, and an area-times-value-per-hectare build from 216.0 million GM hectares with regional price differentials. The three converge within USD 25.2–27.1 billion for 2025 and the midpoint is taken. The evidence base is 70% secondary and 30% primary, with no commissioned survey work this cycle. No third-party market-research study is used, licensed or cited anywhere in the report.
Two boundary disclosures. First, this market is 33.4% of the USD 78.40 billion commercial seed market and is therefore not additive with it: the Global Seed Market report is the base and this is a subset of it. Second, the area denominator matters to the adoption figure. 216.0 million hectares is 28.2% of the 765.9 million hectares of crop area this report tracks, which is the base the forecast is built on; it is not the whole of the world’s harvested cropland, and the share would be materially lower against a full cropland denominator.
Watch list
Six items determine whether 5.90% survives. China’s 2027 area target and whether trait approval keeps pace with planting ambition. The EU delegated and implementing acts on category 1 verification, due by 17 July 2028. Whether triple-stack maize traits actually reach out-licensing in 2027 as signalled. The completion and terms of the Corteva Seed and Crop Protection separation. Any further herbicide label litigation in the United States — the single largest downside variable, because it removes value from tolerance traits across all four majors at once. And the first commercial-scale gene-edited row-crop launches outside North and South America.
None of the six is agronomic. That is the defining characteristic of risk in this market: demand for GM seed is anchored in measured farm-gate return and does not disappear in a downcycle, but the legal right to sell a particular technology can disappear in a season.
Related coverage in this cluster
Read alongside: the Global Seed Market for the USD 78.40 billion base this market sits inside; Global Hybrid Seeds for the germplasm-meets-hybridisation route into the same crops, at USD 31.10 billion; Global Corn (Maize) Seed for the crop that carries 47.2% of this market’s value and the USD 275-a-hectare American seed spend behind it; Global Soybean Seed for the 73.9%-adopted crop and the expired-patent question at its centre; Global Rice Seed for the largest crop on earth with no commercial GM variety at all; Global Forage and Turf Grass Seed for the seed category with no transgenic product anywhere; Global Seed Treatment and Global Vegetable Seeds for the adjacent categories and the same four vendors; and Global Crop Protection for the chemistry side of the corridor, which is the half of the dicamba dependency that gets invoiced separately.
Two articles on this market: Genetically Modified Seed Is Nearly All of the Corn in the Americas and None of the Rice Anywhere — the adoption table behind this forecast and what China’s 57.85 million mu target does to the volume line; and The Trait Is Not the Asset Any More. The Approval Is. — 239 Chinese variety approvals and why Europe at 0.6% of this market is a calendar problem rather than a science one.
About Pheonix Research
Pheonix Research produces market intelligence on agriculture, energy, healthcare, industrials and consumer markets, built from primary operator evidence and official disclosure rather than licensed third-party studies. Every forecast is published with its base-year arithmetic, its segment reconciliations and its triangulation band, so that a reader can reproduce the number rather than take it. This report is part of a nine-report Seeds coverage, which also covers the seed hub, seed treatment, vegetable, hybrid, corn, rice, soybean, forage and turf grass seed markets.
Full report: Global Genetically Modified and Biotech Seeds Market Report, Size, Share and Forecast 2026–2033
